| Similar Articles |
|---|
 |
The Motley Fool
August 9, 2010
Luke Timmerman |
Affymax Lives to Fight Another Day Affymax takes on Amgen with its anemia drug.   |
The Motley Fool
May 17, 2007
Brian Lawler |
Affymax on the Attack Affymax announces its first-quarter financial results. Investors should pay close attention to the future clinical trial results that Hematide will produce and how Affymax's share price reacts. |
The Motley Fool
December 5, 2011
Brian Orelli |
Up 20%, but Uncertainty Still Looms Affymax is still a risky bet. |
The Motley Fool
December 8, 2011
Luke Timmerman |
Affymax Passes FDA Panel Scrutiny, Looks to Challenge Amgen Anemia Drug Many investors wrote off Affymax in June 2010, but was that premature? |
The Motley Fool
December 8, 2011
Brian Orelli |
A Soaring Biotech With Room to Run Affymax gets a leg up from an FDA advisory panel vote. |
The Motley Fool
May 4, 2007
Mike Havrilla |
Taking It to the Affymax Positive clinical data for a potential anemia treatment has the drugmaker's stock on the rise. |
The Motley Fool
October 7, 2010
Anders Bylund |
Affymax Shares Plunged: What You Need to Know Affymax plunged as much as 11.6% in early trading today after an unfavorable ruling in a patent dispute with larger drug developer Johnson & Johnson. |
American Family Physician
November 1, 2003
Riedl & Casillas |
Adverse Drug Reactions: Types and Treatment Options Adverse drug reactions are common. Identifying true drug allergy, however, can be challenging. Complicating factors of drug reactions include the myriad clinical symptoms and multiple mechanisms of drug-host interaction, many of which are poorly understood. |
